~~<i id='3BE578A184'><strike id='3BE578A184'><tt id='3BE578A184'><pre id='3BE578A184'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：leisure time 2025-10-02 04:08:18 - browse：63555

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Questions loom on AstraZeneca cancer drug as safety concerns ebb

entertainment

hotspot

Wikipedia

focus

PriscillaChanandMarkZuckerbergappearvirtuallyatthe2023STATSummit.STATMetafounderMarkZuckerbergandhis

WSS

STAT Readout: Friday, Oct. 20 biotech updates

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Health tech investors get more selective as pandemic boom fades

Roche drug slashes death risk in early

Readout LOUD podcast: Live from the 2023 STAT Summit

UnitedHealth, Optum discontinue NaviHealth name

hotspot

leisure time

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

STAT Summit: Meghan O’Rourke on making chronic illness visible

State Dept. review finds Biden bears some blame for Afghanistan failures

Study on Amgen’s bispecific immunotherapy produces positive data

Virginia high school admissions case could be legal follow

Study on Amgen’s bispecific immunotherapy produces positive data

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Roche drug slashes death risk in early

ChatGPT in medicine: STAT answers readers' burning questions

CZI to create biohub to build anti

hotspot

The problems with dementia villages

CZI to create biohub to build anti

Questions loom on AstraZeneca cancer drug as safety concerns ebb

CZI to create biohub to build anti

Health tech investors get more selective as pandemic boom fades

Roche drug slashes death risk in early

Wikipedia

focus

focus

focus